BACKGROUND: Germline mutations in the BRCA1 and BRCA2 genes have been shown to account for the majority of hereditary breast and ovarian cancers. The purpose of our study was to estimate the incidence and spectrum of pathogenic mutations in BRCA1/2 genes in high-risk Czech families. METHODS: A total of 96 Czech families with recurrent breast and/or ovarian cancer and 55 patients considered to be at high-risk but with no reported family history of cancer were screened for mutations in the BRCA1/2 genes. The entire coding sequence of each gene was analyzed using a combination of the protein truncation test and direct DNA sequencing. RESULTS: A total of 35 mutations in the BRCA1/2 genes were identified in high-risk families (36.5%). Pathogenic mutations were found in 23.3% of breast cancer families and in 59.4% of families with the occurrence of both breast and ovarian cancer. In addition, four mutations were detected in 31 (12.9%) women with early onset breast cancer. One mutation was detected in seven (14.3%) patients affected with both a primary breast and ovarian cancer and another in three (33.3%) patients with a bilateral breast cancer. A total of 3 mutations in BRCA1 were identified among 14 (21.4%) women with a medullary breast carcinoma. Of 151 analyzed individuals, 35 (23.2%) carried a BRCA1 mutation and 9 (6.0%) a BRCA2 mutation. One novel truncating mutation was found in BRCA1 (c.1747A>T) and two in BRCA2 (c.3939delC and c.5763dupT). The 35 identified BRCA1 mutations comprised 13 different alterations. Three recurrent mutations accounted for 71.4% of unrelated individuals with detected gene alterations. The BRCA1 c.5266dupC (5382insC) was detected in 51.4% of mutation positive women. The mutations c.3700_3704del5 and c.181T>G (300T>G) contributed to 11.4% and 8.6% of pathogenic mutations, respectively. A total of eight different mutations were identified in BRCA2. The novel c.5763dupT mutation, which appeared in two unrelated families, was the only recurrent alteration of the BRCA2 gene identified in this study. CONCLUSION: Mutational analysis of BRCA1/2 genes in 151 high-risk patients characterized the spectrum of gene alterations and demonstrated the dominant role of the BRCA1 c.5266dupC allele in hereditary breast and ovarian cancer.

Department of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1690. PubMed

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71. PubMed

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–2090. PubMed

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792. doi: 10.1038/378789a0. PubMed DOI

Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–337. doi: 10.1038/ng0396-333. PubMed DOI

Greene MH. Genetics of breast cancer. Mayo Clin Proc. 1997;72:54–65. PubMed

Couch FJ, Weber BL. Breast cancer. In: Vogelstein B, Kinzler KW, editor. The genetic basis of human cancer. 1. New York: McGraw-Hill; 1998. pp. 537–563.

Thompson D, Easton DF, Breast Cancer Linkage Consortium Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–1365. PubMed

Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13:117–119. doi: 10.1038/ng0596-117. PubMed DOI

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689. doi: 10.1086/301749. PubMed DOI PMC

Breast Cancer Information Core (BIC)

Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD, Pizzichetta MA, Tibiletti MG, Gallo A, Tumolo S, Del Tin L, Boiocchi M. Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int J Cancer. 1998;78:581–586. doi: 10.1002/(SICI)1097-0215(19981123)78:5<581::AID-IJC9>3.0.CO;2-G. PubMed DOI

Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A. BRCA1 and BRCA2 genes: Role in hereditary breast and ovarian cancer in Italy. Int J Cancer. 1999;83:5–9. doi: 10.1002/(SICI)1097-0215(19990924)83:1<5::AID-IJC2>3.0.CO;2-U. PubMed DOI

Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187. doi: 10.1038/ng1096-185. PubMed DOI

Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997;60:1041–1049. PubMed PMC

Hakansson S, Johannsson O, Johansson U, Sellberg G, Loman N, Gerdes A-M, Holmberg E, Dahl N, Pandis N, Kristoffersson U, et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet. 1997;60:1068–1078. PubMed PMC

Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Clough KB, Pouillart P, et al. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Am J Hum Genet. 1977;60:1021–1030. PubMed PMC

Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodriguez-Lopez R, Velasco E, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat. 2003;22:301–312. doi: 10.1002/humu.10260. PubMed DOI

Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997;60:1013–1020. PubMed PMC

Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA. Frequently occurring germline mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet. 1997;60:1239–1242. PubMed PMC

Wagner TMU, Moslinger RA, Muhr D, Langbauer G, Hirtenlehner K, Concin H, Doeller W, Haid A, Lang AH, Mayer P, et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics. Int J Cancer. 1998;77:354–360. doi: 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N. PubMed DOI

Grzybowska E, Zientek H, Jasinska A, Rusin M, Kozlowski P, Sobczak K, Sikorska A, Kwiatkowska E, Gorniak L, Kalinowska E, et al. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mutat. 2000;16:482–490. doi: 10.1002/1098-1004(200012)16:6<482::AID-HUMU5>3.0.CO;2-O. PubMed DOI

Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66:1963–1968. doi: 10.1086/302922. PubMed DOI PMC

van der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 2000;86:737–740. doi: 10.1002/(SICI)1097-0215(20000601)86:5<737::AID-IJC21>3.0.CO;2-1. PubMed DOI

Perkowska M, Brozek I, Wysocka B, Haraldsson K, Sandberg T, Jahansson U, Sellberg G, Borg A, Limon J. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from Northeastern Poland. Hum Mutat. 2003;21:553–554. doi: 10.1002/humu.9139. PubMed DOI

Foretova L, Machackova E, Navratilova M, Pavlu H, Hruba M, Lukesova M, Valik D. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004;23:397–398. doi: 10.1002/humu.9226. PubMed DOI

Pohlreich P, Stribrna J, Kleibl Z, Zikan M, Kalbacova R, Petruzelka L, Konopasek B. Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic. Med Princ Pract. 2003;12:23–29. doi: 10.1159/000068163. PubMed DOI

Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–1490. doi: 10.1200/JCO.20.6.1480. PubMed DOI

den Dunnen JT, Paalman MH. Standardizing mutation nomenclature: Why bother? Hum Mutat. 2003;22:181–182. doi: 10.1002/humu.10262. PubMed DOI

Hogervorst FBL, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995;10:208–212. PubMed

Krainer M, Silva-Arrieta S, Fitzgerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997;336:1416–1421. doi: 10.1056/NEJM199705153362003. PubMed DOI

Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA, UKCCCR Familial Ovarian Cancer Study Group Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. Am J Hum Genet. 1996;58:451–456. PubMed PMC

Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer susceptibility genes? Am J Hum Genet. 1997;60:486–495. PubMed PMC

Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat J-P, Longy M, Guinebretiere J-M, Sauvan R, Noguchi T, et al. Mutations at BRCA1: The medullary breast carcinoma revisited. Cancer Res. 1998;58:1588–1592. PubMed

Maquat LE. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. RNA. 1995;1:453–465. PubMed PMC

Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997;57:828–831. PubMed

King MC, Marks JH, Mandell JB, The New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646. doi: 10.1126/science.1088759. PubMed DOI

Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15:103–105. doi: 10.1038/ng0197-103. PubMed DOI

Thompson D, Easton D, Breast Cancer Linkage Consortium Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410–419. doi: 10.1086/318181. PubMed DOI PMC

Gayther SA, Warren W, Mazoyer S, Russel PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 1995;11:428–433. doi: 10.1038/ng1295-428. PubMed DOI

Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, Ponder BAJ, Olah E. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet. 1997;60:1242–1246. PubMed PMC

Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004;110:683–686. doi: 10.1002/ijc.20162. PubMed DOI

Backe J, Hofferbert S, Skawran B, Dork T, Stuhrmann M, Karstens JH, Untch M, Meindl A, Burgemeister R, Chang-Claude J, Weber BHF. Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol. 1999;72:402–406. doi: 10.1006/gyno.1998.5270. PubMed DOI

Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans DGR, The Early Onset Breast Cancer Study Group Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003;361:1101–1102. doi: 10.1016/S0140-6736(03)12856-5. PubMed DOI

Martinez-Ferrandis JI, Vega A, Chirivella I, Marin-Garcia P, Insa A, Lluch A, Carracedo A, Chaves FJ, Garcia-Conde J, Cervantes A, Armengod M-E. Mutational analysis of BRCA1 and BRCA2 in mediterranean Spanish women with early-onset breast cancer: Identification of three novel pathogenic mutations. Hum Mutat. 2003;22:417–418. doi: 10.1002/humu.9188. PubMed DOI

Yassaee VR, Zeinali S, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, Dalton A. Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res. 2002;4:R6. doi: 10.1186/bcr443. PubMed DOI PMC

Shousha S. Medullary carcinoma of the breast and BRCA1 mutation. Histopathology. 2000;37:182–185. doi: 10.1046/j.1365-2559.2000.00880.x. PubMed DOI

Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316–321. doi: 10.1016/S0140-6736(97)07065-7. PubMed DOI

Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998;16:397–404. PubMed

Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic

Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers

Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases

Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes

Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer

Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic

Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint

Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic